A BESPOKE HEALTHCARE CONSULTING PARTNER
WHAT WE DO
Healthcare System & Policy Research
Market & Regulatory Analysis
Conducting in-depth analysis of healthcare market trends, evolving regulatory landscapes, and competitor activities to help clients navigate complex environments with confidence.
Market Entry Strategy Development
Providing actionable, data-driven recommendations to develop and optimize market entry strategies for successful product launches and sustained growth in Japan’s pharmaceutical sector.
Competitive Intelligence & Strategic Insights
Delivering tailored competitive intelligence and strategic insights to support pharmaceutical companies entering the Japanese market across a range of therapeutic areas.
OUR ENGAGEMENTS
At Scinovo Intel, we deliver bilingual, evidence-based insights that help global pharma clients navigate Japan’s complex healthcare ecosystem. Here are select examples of our recent work:
Obesity & MASH (Japan): Strategic analysis of GLP-1 drug launch landscape, public health policy, and digital health partnership potential.
Cerebrovascular Therapy (Japan): In-depth market assessment for an investigational drug, including care pathways and clinical guideline alignment.
Dementia (Japan): Evaluation of national dementia initiatives (Orange Plan, New Orange Plan) to guide pharma strategy and stakeholder engagement.
ASCVD (India & Japan): Competitive benchmarking and market access mapping for a novel lipid-lowering therapy.
Rare & Metabolic Diseases (Japan): Policy and stakeholder mapping for obesity, cardiovascular, and metabolic conditions.
Ophthalmology (Japan): Healthcare policy review and ecosystem mapping for ophthalmic diseases.
Digital Health (Japan): Exploration of digital tools in chronic disease management and collaboration models with local platforms.
Alzheimer’s (Global): Scientific content development and medical newsletter creation for global medical affairs.
Neonatal RDS & Anemia (Global): Market intelligence for surfactant therapies and HIF-PHI class drugs.
Von Willebrand & FH (Japan): Competitive and epidemiologic research for rare disease and hereditary condition therapies.
Oncology & Neuroscience (Japan): Intelligence on generic approvals and access strategies for CNS and cancer therapies.
Medical Devices (Japan): Regulatory and market readiness study for pediatric enteral syringes.
Breast Cancer (Japan): Identification of unmet needs and underserved patient segments in metastatic breast cancer.
Antimicrobial Resistance (Japan): Research on AMR policy landscape and antibiotic prescription trends to support stewardship and pharma positioning.
Cyberbullying Policy (Japan): Legal and public health mapping to support mental health-focused awareness and education strategies.
WHY US ?
Proven industry expertise in Pharma and healthcare research
Japan-focused - In-depth knowledge of local healthcare system
Tailored - Research built around your specific questions and goals
Insight-driven - Strategic actionable findings - not just data
Trusted & Agile - Timely, confidential and aligned with your evolving needs